Compare Mesoblast Limited (MESO) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Mesoblast Limited trades at $14.33 (market cap $1.75B), while iShares 1 3 Year Treasury Bond ETF trades at $81.18 (market cap $26.68B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 15.2× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 4,077,691). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| MESO | SHY | |
|---|---|---|
Market Cap | $1.75B | $26.68B |
Volume | 239,027 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $20.96 | $83.18 |
52-Week Low | $13.19 | $81.05 |
Typical Hold Time | 14 Days | 63 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
SHY trades at $81.175, up 0.02% on the day, amid a bearish technical signal driven by moving averages. The stock shows neutral oscillators but faces selling pressure from the ADX indicator. Recent corporate actions include dividends scheduled for late 2026, with payouts of $0.24-$0.25 per share. The broader bond market context, with rising yields, influences sentiment around short-term bond ETFs like SHY.
The outlook for SHY is cautious due to technical bearishness and macroeconomic headwinds from rising interest rates. Opportunities exist for income-focused investors via dividends, but risks include prolonged bond market volatility and Fed policy uncertainty. Investor sentiment remains mixed, balancing yield appeal against duration risk in a higher-rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
